AnaptysBio, Inc (ANAB) stock
ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026Market cap $1.73BP/E –Yield –
AnaptysBio EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
AnaptysBio's EPS for the twelve months ending Sep 30, 2025 was -$2.72. For fiscal 2025 it was -$0.44. The highest annual figure on record is -$0.44 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.44 | – |
| FY2024 | Dec 31, 2024 | -$4.92 | – |
| FY2023 | Dec 31, 2023 | -$6.08 | – |
| FY2022 | Dec 31, 2022 | -$4.57 | – |
| FY2021 | Dec 31, 2021 | -$2.11 | – |
| FY2020 | Dec 31, 2020 | -$0.73 | – |
| FY2019 | Dec 31, 2019 | -$3.60 | – |
| FY2018 | Dec 31, 2018 | -$2.50 | – |
| FY2017 | Dec 31, 2017 | -$1.52 | – |
| FY2016 | Dec 31, 2016 | -$1.62 | – |
| FY2015 | Dec 31, 2015 | -$2.12 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0.11 | – |
| Q2 FY2026 | Jun 30, 2026 | $3.97 | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.84 | – |
| Q3 FY2025 | Sep 30, 2025 | $0.52 | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.34 | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.28 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.62 | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.14 | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.71 | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.64 | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.59 | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.41 | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.50 | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.58 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.93 | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.18 | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.15 | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.31 | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.18 | -195.9% |
| Q3 FY2021 | Sep 30, 2021 | -$0.24 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.02 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.66 | – |
| Q4 FY2020 | Dec 31, 2020 | $1.23 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.87 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.79 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.30 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.75 | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.15 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.89 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.82 | – |
| Q4 FY2018 | Dec 31, 2018 | -$0.64 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.66 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.57 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.63 | – |
| Q4 FY2017 | Dec 31, 2017 | -$0.30 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.45 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.13 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.75 | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.73 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?